Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, Nakamura Y, Kawaguchi Y, Watabe T. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos. 1997;25(5):270–3.

PubMed  Google Scholar 

Iga K. Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. J Pharm Sci. 2015;104(4):1478–91.

Article  CAS  PubMed  Google Scholar 

Iga K. Simulation of metabolic drug-drug interactions perpetrated by fluvoxamine using hybridized two-compartment hepatic drug-pool-based tube modeling and estimation of in vivo inhibition constants. J Pharm Sci. 2015;104(10):3565–77.

Article  CAS  PubMed  Google Scholar 

Iga K. Dynamic and static simulations of fluvoxamine-perpetrated drug-drug interactions using multiple cytochrome P450 inhibition modeling, and determination of perpetrator-specific CYP isoform inhibition constants and fractional CYP isoform contributions to victim clearance. J Pharm Sci. 2016;105(3):1307–17.

Article  CAS  PubMed  Google Scholar 

Iga K, Kiriyama A. Simulations of cytochrome P450 3A4-mediated drug-drug interactions by simple two-compartment model-assisted static method. J Pharm Sci. 2017;106(5):1426–38.

Article  CAS  PubMed  Google Scholar 

Iga K, Kiriyama A. Usefulness of two-compartment model-assisted and static overall inhibitory-activity method for prediction of drug-drug interaction. Biol Pharm Bull. 2017;40(12):2024–37.

Article  CAS  PubMed  Google Scholar 

Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016;68(1):168–241.

Article  PubMed  Google Scholar 

Karonen T, Neuvonen PJ, Backman JT. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol. 2012;73(2):257–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Itkonen MK, Tornio A, Filppula AM, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel but not prasugrel significantly inhibits the CYP2C8-mediated metabolism of montelukast in humans. Clin Pharmacol Ther. 2018;104(3):495–504.

Article  CAS  PubMed  Google Scholar 

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel and gemfibrozil strongly inhibit the CYP2C8-dependent formation of 3-hydroxydesloratadine and increase desloratadine exposure in humans. Drug Metab Dispos. 2019;47(4):377–85.

Article  CAS  PubMed  Google Scholar 

Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia. 2003;46(3):347–51.

Article  CAS  PubMed  Google Scholar 

Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006;34(1):191–7.

Article  CAS  PubMed  Google Scholar 

Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, Neuvonen PJ. CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos. 2009;37(12):2359–66.

Article  CAS  PubMed  Google Scholar 

Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, Backman JT. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther. 2014;96(4):498–507.

Article  CAS  PubMed  Google Scholar 

Kahma H, Filppula AM, Neuvonen M, Tarkiainen EK, Tornio A, Holmberg MT, Itkonen MK, Finel M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel carboxylic acid glucuronidation is mediated mainly by UGT2B7, UGT2B4, and UGT2B17: implications for pharmacogenetics and drug-drug interactions. Drug Metab Dispos. 2018;46(2):141–50.

Article  CAS  PubMed  Google Scholar 

Takagi M, Sakamoto M, Itoh T, Fujiwara R. Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. Drug Metab Pharmacokinet. 2015;30(4):288–94.

Article  CAS  PubMed  Google Scholar 

Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther. 2011;89(4):579–86.

Article  CAS  PubMed  Google Scholar 

Shah MB. Inhibition of CYP2C8 by acyl glucuronides of gemfibrozil and clopidogrel: pharmacological significance, progress and challenges. Biomolecules. 2022;12(9):1218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tornio A, Neuvonen PJ, Niemi M, Backman JT. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin Drug Metab Toxicol. 2017;13(1):83–95.

Article  CAS  PubMed  Google Scholar 

Nishihara M, Sudo M, Kamiguchi H, Kawaguchi N, Maeshiba Y, Kiyota Y, Takahashi J, Tagawa Y, Kondo T, Asahi S. Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α and -δ, in rats and monkeys and comparison with humans in vitro. Drug Metab Pharmacokinet. 2012;27(2):223–31.

Article  CAS  PubMed  Google Scholar 

Nishihara M, Sudo M, Kawaguchi N, Takahashi J, Kiyota Y, Kondo T, Asahi S. An unusual metabolic pathway of sipoglitazar, a novel antidiabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide. Drug Metab Dispos. 2012;40(2):249–58.

Article  CAS  PubMed  Google Scholar 

Stringer F, Scott G, Valbuena M, Kinley J, Nishihara M, Urquhart R. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent. Eur J Clin Pharmacol. 2013;69(3):423–30.

Article  CAS  PubMed  Google Scholar 

Kazmi F, Barbara JE, Yerino P, Parkinson A. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab Dispos. 2015;43(4):523–33.

Article  CAS  PubMed  Google Scholar 

Kazmi F, Yerino P, Barbara JE, Parkinson A. Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015;43:1294–302.

Article  CAS  PubMed  Google Scholar 

Gan J, Chen W, Shen H, Gao L, Hong Y, Tian Y, Li W, Zhang Y, Tang Y, Zhang H, Humphreys WG, Rodrigues AD. Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br J Clin Pharmacol. 2010;70(6):870–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

VandenbBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos. 2011;39(9):1546–54.

Article  Google Scholar 

Cardoso JO, Oliveira RV, Lu JBL, Desta Z. In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015;43(12):1905–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Y, Fu Y, Khojasteh SC, Dalvie D, Zhang D. Glucuronides as potential anionic substrates of human cytochrome P450 2C8 (CYP2C8). J Med Chem. 2017;60(21):8691–705.

Article  CAS  PubMed  Google Scholar 

Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL. System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet. 2010;25(1):16–27.

Article  CAS  PubMed  Google Scholar 

Liu Y, Coughtrie MWH. Revisiting the latency of uridine diphosphate-glucuronosyltransferases (UGTs)-how does the endoplasmic reticulum membrane influence their function? Pharmaceutics. 2017;9(3):32.

Article  PubMed  PubMed Central  Google Scholar 

Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther. 2005;77(5):404–14.

Article  CAS  PubMed  Google Scholar 

Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab Dispos. 2016;44(8):1364–71.

Article  CAS  PubMed  Google Scholar 

Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002;72(6):685–91.

Article  CAS  PubMed  Google Scholar 

Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet. 2002;41Suppl 1:29–35.

Article  Google Scholar 

Banfield C, Herron J, Keung A, Padhi D, Affrime M. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet. 2002;41Suppl